Search Within

Heiko Schoder

  1. "Department of Medicine"
Formats
  1. Journal Article (135)
  2. Meeting Abstract (124)
  3. Research Letter (4)
  4. Book Section (1)
  5. Editorial (1)
  6. Review (1)
Groups
  1. Department of Medicine (266)
  2. Molecular Imaging and Therapy Service (266)
  3. Radiology, Department of (266)
  4. Hematologic Malignancies, Division of (153)
  5. Center for Hematologic Malignancies (141)
  6. Solid Tumor Oncology Division (132)

More Groups

People
  1. Andrew Zelenetz (66)
  2. Alison Moskowitz (59)
  3. David Straus (56)
  4. Ariela Noy (55)
  5. Maria Palomba (53)
  6. Paul Hamlin (51)

More People

Years
  1. 2025 (8)
  2. 2024 (26)
  3. 2023 (28)
  4. 2022 (14)
  5. 2021 (21)
  6. 2020 (16)

More Years

Publications
  1. Journal of Clinical Oncology (51)
  2. Blood (49)
  3. Journal of Nuclear Medicine (25)
  4. International Journal of Radiation Oncology, Biology, Physics (22)
  5. Hematological Oncology (11)
  6. European Journal of Nuclear Medicine and Molecular Imaging (9)

More Publications

Publishers
  1. American Society of Hematology (55)
  2. American Society of Clinical Oncology (51)
  3. Elsevier Inc. (31)
  4. Society of Nuclear Medicine (25)
  5. Springer (19)
  6. Wiley Blackwell (17)

More Publishers

Results (266)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Development and validation of diagnostic interpretation criteria for evaluation of F-18 Fluoromisonidazole hypoxia PET/CT – Inter-reader reliability and accuracy
    Meeting Abstract

    Wray, R.; Mauguen, A.; Michaud, L.; Leithner, D.; Sherman, E.; Riaz, N.; Humm, J.; Mirtcheva, R.; Boyle, J. O.; Wong, R. J.; more...
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save
  • Tumor volume predicts for baseline hypoxia status in HPV related oropharyngeal carcinomas (OPC) that underwent major radiation de-escalation: The 30 Reduction in Oropharyngeal Cancer Trial
    Meeting Abstract

    Han, J.; Diplas, B.; Paudyal, R.; Oh, J. H.; Sherman, E.; Schoder, H.; Hatzoglou, V.; Yu, Y.; Wong, R. J.; Wray, R.; more...
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save
  • Treatment response and clinical outcomes of well-differentiated (WD) high-grade (HG) neuroendocrine tumors (NETs) to (177)Lu-DOTATATE
    Meeting Abstract

    Coffman, K.; Bodei, L.; Le, T.; Choi, Y.; Chou, J.; Capanu, M.; Dunphy, M.; Fox, J.; Grewal, R.; Reddy, R.; more...
    Pancreas (2022)

    Fulltext@MSK | Save
  • Blood-based genomic assessment of clinical efficacy and toxicity of (177)Lu-DOTATATE of neuroendocrine tumors
    Meeting Abstract

    Bodei, L.; Raj, N.; Do, K. G.; Krebs, S.; Reidy-Lagunes, D.; Kidd, M.; Drozdov, I.; Modlin, I.; Schöder, H.
    Pancreas (2022)

    Fulltext@MSK | Save
  • Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma
    Journal Article

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood Cancer Journal (2022)

    Fulltext@MSK | Save
  • Phase I/Ib study of the efficacy and safety of buparlisib and ibrutinib therapy in MCL, FL, and DLBCL with serial cell-free DNA monitoring
    Journal Article

    Stewart, C. M.; Michaud, L.; Whiting, K.; Nakajima, R.; Nichols, C.; De Frank, S.; Hamlin, P. A. Jr; Matasar, M. J.; Gerecitano, J. F.; Drullinsky, P.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Quantitative change in metabolic tumor volume may assist in distinguishing between pseudoprogressors and responders in patients with relapsed/refractory classical Hodgkin lymphoma treated with PD-1 blockade
    Meeting Abstract

    Wills, B.; Michaud, L.; Schöder, H.; Ganesan, N.; Moskowitz, C. H.; Straus, D. J.; Falchi, L.; Matasar, M. J.; Zelenetz, A. D.; Joffe, E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Favorable outcomes of patients with limited-stage ocular adnexal DLBCL treated in the rituximab era: Long-term follow-up of a single center experience
    Meeting Abstract

    Qualls, D.; Batlevi, C. L.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; Kumar, A.; Matasar, M. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Effect of brentuximab vedotin addition to chemotherapy and prognostic factors in patients with relapsed/refractory hodgkin lymphoma: A large multi-trial analysis based on individual patient data
    Meeting Abstract

    Driessen, J.; de Wit, F.; Herrera, A. F.; Zinzani, P. L. L.; LaCasce, A. S.; Moskowitz, C. H.; Garcia-Sanz, R.; Cole, P. D.; Fuchs, M.; Mueller, H.; more...
    Blood (2021)

    Fulltext@MSK | Save